Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...
Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the publication of a peer-reviewed research article entitled ...
The Advocate highlights social inequality through original stories and opinions, and content generated by fellow NNPA and other publications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results